Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Thorac Cancer. 2020 Mar;11(3):810-818. doi: 10.1111/1759-7714.13327. Epub 2020 Feb 4.

Abstract

The increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune-related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been largely ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases. KEY POINTS: This review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor-related ocular adverse events.

Keywords: Immune checkpoint inhibitor; immune-related adverse events (irAEs); ocular toxicities; targeted therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / therapy*
  • Eye Diseases / chemically induced
  • Eye Diseases / diagnosis*
  • Eye Diseases / therapy*
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Practice Guidelines as Topic / standards*
  • Prognosis

Substances

  • Immune Checkpoint Inhibitors